Last reviewed · How we verify

NCT05109273: WATER ATTAC

Atrioventricular Nodal Reentrant Tachycardia Ablation With Irrigated Catheter and Three-dimensional Electroanatomic Mapping

Active, enrolled Last updated 14 May 2024
What this trial tests

trial testing Transcatheter ablation in Atrioventricular Nodal Re Entrant Tachycardia in 289 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 December 2021
Primary endpoint
30 September 2024
31 October 2024

Quick facts

Lead sponsorUniversity Hospital of Ferrara
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment289
Start date1 December 2021
Primary completion30 September 2024
Estimated completion31 October 2024
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital of Ferrara

Who can join

18 and older, any sex, with Atrioventricular Nodal Re Entrant Tachycardia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The WATER ATTAC study aims at multicentric, longitudinal, perspective evaluation of safety and efficacy of atrioventricular nodal reentrant tachycardia (AVNRT) performed combining irrigated ablation catheter and three-dimensional electroanatomic mapping system. Efficacy and rate of complications will be evaluated over medium and long term follow-up.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University Hospital of Ferrara trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05109273.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing